Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in three upcoming investor conferences. The presentations will be available live and on-demand for 90 days on the company's IR homepage.

The conferences include:

• The Lytham Partners Fall 2024 Investor Conference on October 1, 2024, at 10:15 am EDT, featuring CFO Melissa Tosca.
• The Maxim Virtual Healthcare Conference | Ophthalmology Panel on October 15, 2024, at 11:00 am EDT, with CEO Brian M. Strem, Ph.D.
• The LD Micro Conference on October 29, 2024, at 4:00 pm EDT, presented by CFO Melissa Tosca.

Investors can register for each event through provided links and arrange meetings with management where applicable.

Encinitas, California--(Newsfile Corp. - September 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in the following investor conferences. The presentations will be accessible live and on-demand for 90 days from our IR homepage (ir.kiorapharma.com).

• Lytham Partners Fall 2024 Investor Conference.

Monday, October 1, 2024 at 10:15 am EDT
Presenter: Melissa Tosca, Chief Financial Officer
Click here to register and view
To arrange a meeting with management, please email 1×1@lythampartners.com

• Maxim Virtual Healthcare Conference | Ophthalmology Panel

Tuesday, October 15, 2024 at 11:00 am EDT
Presenter: Brian M. Strem, Ph.D., Chief Executive Officer
Click here to sign up (account creation required), register and view

• LD Micro Conference

Tuesday, October 29 at 4:00 pm EDT
Presenter: Melissa Tosca, Chief Financial Officer
Click here to register and view

About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

In addition to news releases and SEC filings, we expect to post information on our website (www.kiorapharma.com) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Contacts:
Investors
investors@kiorapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224520

FAQ

When is Kiora Pharmaceuticals (KPRX) participating in the Lytham Partners Fall 2024 Investor Conference?

Kiora Pharmaceuticals (KPRX) is participating in the Lytham Partners Fall 2024 Investor Conference on Monday, October 1, 2024, at 10:15 am EDT.

Who is presenting for Kiora Pharmaceuticals (KPRX) at the Maxim Virtual Healthcare Conference?

Brian M. Strem, Ph.D., Chief Executive Officer of Kiora Pharmaceuticals (KPRX), is presenting at the Maxim Virtual Healthcare Conference | Ophthalmology Panel on Tuesday, October 15, 2024, at 11:00 am EDT.

What is the date and time of Kiora Pharmaceuticals' (KPRX) presentation at the LD Micro Conference?

Kiora Pharmaceuticals (KPRX) is presenting at the LD Micro Conference on Tuesday, October 29, 2024, at 4:00 pm EDT.

How long will Kiora Pharmaceuticals' (KPRX) investor conference presentations be available on-demand?

Kiora Pharmaceuticals' (KPRX) investor conference presentations will be available on-demand for 90 days from the company's IR homepage.

Where can investors view Kiora Pharmaceuticals' (KPRX) upcoming investor conference presentations?

Investors can view Kiora Pharmaceuticals' (KPRX) upcoming investor conference presentations live and on-demand on the company's IR homepage at ir.kiorapharma.com.